 CAMBRIDGE, Mass., Jan. 28, 2021 GLOBE NEWSWIRE -- Evelo Biosciences, Inc. Nasdaq: EVLO Evelo, a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it intends to offer and sell, subject to market and other conditions, 50 million of its common stock in an underwritten public offering. Evelo expects to grant the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 7.5 million of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Evelo. 